ArticleNPJ vaccines2025
An mRNA vaccine provides effective protection against Duck Tembusu Virus infection.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Quercetin exhibits antiviral activity against duck Tembusu virus in vitro and in vivo.Poultry science · 2026Article
- Advancements in nanomaterial-based adjuvants for animal vaccines.Materials today. Bio · 2026Article
- mRNA Vaccine Against Japanese Encephalitis Virus Genotype IV Protects Against Lethal Infection.Viruses · 2026Article
- The scorpion peptide Eval418 inhibits duck Tembusu virus replication by disrupting viral structure and early-stage infection.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
As an emerging flavivirus, Duck Tembusu virus (DTMUV) causes severe neurological disorder and acute egg drop syndrome in poultry. Herein, we report the development of a highly effective mRNA vaccine against DTMUV using lipid nanoparticle (LNP) delivery technology. We engineered an mRNA construct encoding the pre-membrane (prM) and envelope (E) proteins of DTMUV, with an upstream signal peptide to enhance secretion. Two doses of our mRNA vaccine elicited robust neutralizing antibody titers and conferred 100% protection against challenge with a prevalent virulent DTMUV strain. Notably, in a head-to-head comparison, the neutralizing antibody titers induced by our mRNA vaccine were approximately 40-fold of a commercial live-attenuated vaccine (FX2010-180P). Importantly, our mRNA vaccine demonstrated efficient maternal antibody transfer via egg yolk deposition, indicating the potential for protecting offspring through maternal immunity. These findings demonstrate the superiority of our mRNA vaccine platform, as well as the feasibility of applying mRNA vaccines in poultry.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.